Greta Petazzoni

Mrs. Greta Petazzoni

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
Angioletta LasagnaAngioletta Lasagna
Angioletta Lasagna
MAMara De Amici
Mara De Amici
CRChiara Rossi
Chiara Rossi
VZValentina Zuccaro
Valentina Zuccaro
MCMarta Corbella
Marta Corbella
Paolo PedrazzoliPaolo Pedrazzoli
Paolo Pedrazzoli
The interactions between aromatase inhibitors (AI) in breast cancer (BC) and gut microbiota (GM) have not been completely established yet. The aim of the study is to evaluate the bio-diversity of GM and the relationship between GM, inflammation and tumor-infiltrating lymphocytes (TILs) in postmenopausal women with BC during adjuvant AI treatment compared to women with disease relapse during or after one year of AI therapy (“endocrine-resistant”). We conducted a monocenter observational case-control study. Eighty-four women with BC (8 cases, 76 controls) were enrolled from 2019 to 2021. We observed a significant difference in the mean microbial abundance between the two groups for the taxonomic rank of order (p 0.035) and family (p 0.029); specifically, the case group showed higher diversity than the control group. Veillonella reached its maximum abundance in cases (p 0.022). Cytokine levels were compared among the groups created considering the TILs levels. We obtained a statistically significant difference (p 0.045) in IL-17 levels among the groups, with patients with low TILs levels showing a higher median value for IL-17 (0.15 vs. 0.08 pg/mL). Further studies about the bio-diversity in women with BC may lead to the development of new biomarkers and targeted interventions.

23 August 2024 in The Lancet Microbe
Verified
Journal Article
Open access
HTHarry A Thorpe
Harry A Thorpe
MPMaiju Pesonen
Maiju Pesonen
MCMarta Corbella
Marta Corbella
HPHenri Pesonen
Henri Pesonen
SGStefano Gaiarsa
Stefano Gaiarsa
JCJukka Corander
Jukka Corander
Nosocomial infections pose a considerable risk to patients who are susceptible, and this is particularly acute in intensive care units when hospital-associated bacteria are endemic. During the first wave of the COVID-19 pandemic, the surge of patients presented a significant obstacle to the effectiveness of infection control measures. We aimed to assess the risks and extent of nosocomial pathogen transmission under a high patient burden by designing a novel bacterial pan-pathogen deep-sequencing approach that could be integrated with standard clinical surveillance and diagnostics workflows. We did a prospective cohort study in a region of northern Italy that was severely affected by the first wave of the COVID-19 pandemic. Inpatients on both ordinary and intensive care unit (ICU) wards at the San Matteo hospital, Pavia were sampled on multiple occasions to identify bacterial pathogens from respiratory, nasal, and rectal samples. Diagnostic samples collected between April 7 and May 10, 2020 were cultured on six different selective media designed to enrich for Acinetobacter baumannii, Escherichia coli, Enterococcus faecium, Enterococcus faecalis, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae, and DNA from each plate with positive growth was deep sequenced en masse. We used mSWEEP and mGEMS to bin sequencing reads by sequence cluster for each species, followed by mapping with snippy to generate high quality alignments. Antimicrobial resistance genes were detected by use of ARIBA and CARD. Estimates of hospital transmission were obtained from pairwise bacterial single nucleotide polymorphism distances, partitioned by within-patient and between-patient samples. Finally, we compared the accuracy of our binned Acinetobacter baumannii genomes with those obtained by single colony whole-genome sequencing of isolates from the same hospital. We recruited patients from March 1 to May 7, 2020. The pathogen population among the patients was large and diverse, with 2148 species detections overall among the 2418 sequenced samples from the 256 patients. In total, 55 sequence clusters from key pathogen species were detected at least five times. The antimicrobial resistance gene prevalence was correspondingly high, with key carbapenemase and extended spectrum ß-lactamase genes detected in at least 50 (40%) of 125 patients in ICUs. Using high-resolution mapping to infer transmission, we established that hospital transmission was likely to be a significant mode of acquisition for each of the pathogen species. Finally, comparison with single colony Acinetobacter baumannii genomes showed that the resolution offered by deep sequencing was equivalent to single-colony sequencing, with the additional benefit of detection of co-colonisation of highly similar strains. Our study shows that a culture-based deep-sequencing approach is a possible route towards improving future pathogen surveillance and infection control at hospitals. Future studies should be designed to directly compare the accuracy, cost, and feasibility of culture-based deep sequencing with single colony whole-genome sequencing on a range of bacterial species. Wellcome Trust, European Research Council, Academy of Finland Flagship program, Trond Mohn Foundation, and Research Council of Norway.

19 October 2023 in Eurosurveillance
Verified
Journal Article
Open access
IMIrene Mileto
Irene Mileto
GPGreta Petazzoni
Greta Petazzoni
MCMarta Corbella
Marta Corbella
SGStefano Gaiarsa
Stefano Gaiarsa
CMCristina Merla
Cristina Merla
Fausto BaldantiFausto Baldanti
Fausto Baldanti
New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae (Kp) ST147 caused a large multi-hospital outbreak in Italy from 2018 to 2021. We describe a new ST6668 NDM-producing Kp clone, belonging to CC147, which rapidly spread across hospitals in the Pavia province (Northern Italy) from February to August 2023. Genomic analyses revealed that ST6668 is different from ST147 and fast evolving. As shown here, genomic surveillance programmes are useful for tracking the spread of new clones with reduced susceptibility to most antibiotics.

12 February 2025 in Journal of Infection and Public Health
Verified
Journal Article
Open access
MCMarta Corbella
Marta Corbella
CMCristina Merla
Cristina Merla
AKAngela Kuka
Angela Kuka
IMIrene Mileto
Irene Mileto
GPGreta Petazzoni
Greta Petazzoni
PCPatrizia Cambieri
Patrizia Cambieri
During 2022 and 2023, a large upsurge of cases of Group A Streptococcus (GAS) infection has struck many countries worldwide. This large epidemic event was caused by a diminished level of immunity after COVID-19 social restrictions and was fostered mainly by the emm1 genotype of the bacterium. We characterized the genomes of the GAS isolates that caused bloodstream infections in the last ten years in a 900-bed hospital in Northern Italy. We obtained short-read genomes, which we used for emm typing and to analyze the antimicrobial resistance and virulence gene content. Moreover, we contextualized the isolates in an epidemiological point of view using both ortholog-based and SNP-based phylogeny. In the last ten years, we registered two upsurges of GAS cases in the study hospital: one in 2023 (in line with the global epidemiological situation), and one in 2016 (local, but observed also in another recent Italian study). The genomic analysis of the bloodstream infection isolates showed the circulation of multiple emm types, of which emm1, emm12, and emm4 characterized the two large epidemic events. Notably, the 2016 peak was mainly fostered by the M1Global and emm4 genotypes, in contrast with the rise of M1UK observed in the UK in the pre-pandemic years. Phylogeny analysis showed the presence of multiple monophyla of local strains. Despite our genomes being obtained from blood-culture isolates, we did not observe any increased presence of virulence or antimicrobial resistance genes. Our results further confirm the role of emm1 as the most prevalent genotype worldwide. However, we also unveiled the central role of genotype emm4 in the 2016 epidemic event, described in the study hospital. Finally, our results suggest the presence of multiple locally persistent strains. Among these, we underlined the presence of a multi-drug resistant strain of emm92.

17 May 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
VZValentina Zuccaro
Valentina Zuccaro
GPGreta Petazzoni
Greta Petazzoni
IMIrene Mileto
Irene Mileto
MCMarta Corbella
Marta Corbella
EAErika Asperges
Erika Asperges
Raffaele BrunoRaffaele Bruno
Raffaele Bruno
Several studies have strengthened the link between the gut microbiota (GM) and the response to immunotherapy in patients with tumors, highlighting the potential role of GM as a biomarker of response. Targeted therapies including B-cell receptor (BCR) inhibitors (BCRi) represent the newest approach to the treatment of chronic lymphocytic leukemia (CLL); however, not all patients achieve a satisfactory response, and immune-related adverse events (irAEs) can also impact the efficacy. The aim of the study was to compare GM biodiversity in patients with CLL, treated with BCRi for at least 12 months. Twelve patients were enrolled: 10 patients in the responder group (R) and 2 patients in the non-responder group (NR). We identified seven patients (58.3%) who experienced adverse reactions (AE). Although we did not observe a significant difference across the study population in terms of relative abundance and alpha and beta diversity, we found a differing distribution of bacterial taxa between the analyzed groups. We noted a higher level of the class Bacteroidia and the order Bacteroidales in the R group, and an inversion in the Firmicutes and Bacteroidetes ratio in the AE group. No prior studies have focused on linking GM and response to BCRi in these patients. Although the analyses are preliminary, they provide suggestions to guide future research.

24 June 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
MCMarta Colaneri
Marta Colaneri
DCDomenico Di Carlo
Domenico Di Carlo
AAAlessandro Amatu
Alessandro Amatu
LMLea Nadia Marvulli
Lea Nadia Marvulli
MCMarta Corbella
Marta Corbella
Raffaele BrunoRaffaele Bruno
Raffaele Bruno
The guidelines on ventilator-associated pneumonia (VAP) recommend an empiric therapy against methicillin-resistant Staphylococcus aureus (MRSA) according to its prevalence rate. Considering the MRSA and MSSA VAP prevalence over the last 9 years in our tertiary care hospital, we assessed the clinical value of the MRSA nasal-swab screening in either predicting or ruling out MRSA VAP. We extracted the data of 1461 patients with positive bronchoalveolar lavage (BAL). Regarding the MRSA nasal-swab screening, 170 patients were positive for MRSA or MSSA. Overall, MRSA had a high prevalence in our ICU. Despite the COVID-19 pandemic, there was a significant downward trend in MRSA prevalence, while MSSA remained steady over time. Having VAP due to MRSA did not have any impact on LOS and mortality. Finally, the MRSA nasal-swab testing demonstrated a very high negative predictive value for MRSA VAP. Our results suggested the potential value of a patient-centered approach to improve antibiotic stewardship.